U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014735) titled 'Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM' on April 18, 2023.
Brief Summary: Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance. Drugs like moxifloxacin can further exacerbate this effect, especially in those with diabetes. A previous trial on Type 1 diabetes suggested that hyperglycaemia and moxifloxacin have additive effects, prompting an investigation into whether similar effects occur in Type 2 diabetes (T2DM), particularly in individuals with hi...